September 27, 2018 Go or no go? Ionis, Sanofi, Regeneron and Roche await big regulatory decisions October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a make-or-break FDA verdict.
August 06, 2018 Almirall spots an opportunity The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.
August 03, 2018 Upcoming events – Antibiotics from Insmed and Paratek face consecutive panels Make-or-break FDA adcoms beckon for two antibiotics.